Zhou et al., 2015 - Google Patents
Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of RasZhou et al., 2015
View PDF- Document ID
- 12328047878002332251
- Author
- Zhou F
- Krishnamurthy J
- Wei Y
- Li M
- Hunt K
- Johanning G
- Cooper L
- Wang-Johanning F
- Publication year
- Publication venue
- Oncoimmunology
External Links
Snippet
We have previously reported that human endogenous retrovirus-K (HERV-K) envelope (env) protein is a tumor-associated antigen (TAA) for cancer vaccines, and that its antibodies (mAbs) possess antitumor activity against cancer. In this study, a chimeric antigen receptor …
- 210000001744 T-Lymphocytes 0 title abstract description 180
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras | |
| Cao et al. | ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression | |
| Marin et al. | Cellular senescence is immunogenic and promotes antitumor immunity | |
| Bagati et al. | Integrin αvβ6–TGFβ–SOX4 pathway drives immune evasion in triple-negative breast cancer | |
| Huang et al. | miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy | |
| Leclerc et al. | Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1 | |
| Wu et al. | Anti-CD105 antibody eliminates tumor microenvironment cells and enhances anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells | |
| Kailayangiri et al. | Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G | |
| Orlando et al. | Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma | |
| Zingg et al. | The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy | |
| Lu et al. | JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer | |
| Gao et al. | Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma | |
| Panjwani et al. | Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma | |
| Carter et al. | An ARC-regulated IL1β/Cox-2/PGE2/β-Catenin/ARC circuit controls leukemia–microenvironment interactions and confers drug resistance in AML | |
| Cho et al. | Cytotoxicity of activated natural killer cells against pediatric solid tumors | |
| Zhong et al. | Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands | |
| Shiina et al. | CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains | |
| Mittendorf et al. | PD-L1 expression in triple-negative breast cancer | |
| Gururajan et al. | miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer | |
| Hu et al. | LunX-CAR T cells as a targeted therapy for non-small cell lung cancer | |
| Bauman et al. | Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting | |
| Secondini et al. | Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade | |
| Wehrli et al. | Mesothelin CAR T cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma | |
| Ablett et al. | A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity | |
| Galore-Haskel et al. | A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme |